+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.

Age: 5Years - 17YearsAll GendersPhase 3
104 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of GSK5784283 Felcorekibart compared with a placebo in adults aged 40 to 80 years who have moderate to very severe chronic obstructive pulmonary disease COPD with frequent flare-ups. This phase 3 trial aims to determine if adding GSK5784283 to standard care can better reduce the annual rate of moderate and severe COPD exacerbations. Participants will be randomly assigned to receive either GSK5784283 plus their usual COPD treatment or a matching placebo along with standard care. The study will last up to 78 weeks, during which the rate of COPD flare-ups, lung function changes, and quality of life will be assessed. Both groups will continue their regular COPD medications, including inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta-agonists. During the study, participants will have regular visits for health assessments, lung function tests, and questionnaires about respiratory symptoms and quality of life. Researchers will monitor safety and track how often moderate or severe COPD exacerbations occur. The main outcome measured is the annualized rate of these exacerbations up to week 78. The total study duration may be up to nearly four years, including follow-up and monitoring.

Age: 40Years - 80YearsAll GendersPhase 3
4 locations